je.st
news
Tag: cubist
Merck to buy Cubist Pharmaceuticals for $9.5 billion
2014-12-08 14:13:42| Biotech - Topix.net
Drug giant Merck said it will buy Cubist and a slate of medicines administered in the hospital setting, many for bacterial infections, for about $9.5 billion, for $102 a share in cash. The deal represents a 35 percent premium to Cubist's average stock price in the last five trading days, Merck said in a statement on Monday.
Tags: buy
billion
pharmaceuticals
merck
Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
2014-12-08 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & LEXINGTON, Mass. Acquisition Augments Mercks Strong Foundation and Opportunity for Growth in Hospital Acute Care Market KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubists average stock price for the most recent five trading days. Language: English Contact: MerckMedia Contacts:Lainie Keller, 908-406-1459orSteve Cragle, 908-740-1801orInvestor Contacts:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879orCubistMedia Contact:Julie DiCarlo, 781-860-8063orInvestor Contact:Eileen C. McIntyre, 781-860-8100 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: CBST Exchange: NASDAQ read more
Tags: share
cash
acquire
pharmaceuticals
Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT
2014-12-06 06:44:09| Biotech - Topix.net
Merck & Co Inc is in talks to acquire Cubist Pharmaceuticals Inc for more than $7 billion in a deal that could be announced as early as next week, the New York Times reported on Friday, citing people briefed on the matter. Merck will likely pay roughly $100 a share for Cubist, valuing the company that makes drugs to fight superbugs, in the range of $7.5 billion, the people said.
Tags: than
billion
talks
acquire
Bonney to retire as CEO of Cubist, current COO to take over
2014-10-20 19:58:51| Biotech - Topix.net
Cubist CEO Mike Bonney, who oversaw the most successful U.S. launch ever of an intravenous antibiotic, Cubicin, as well as the acquisition of two firms last year, is stepping down after 11 years.
Cubist sees promising test results in treating children with C. difficile
2014-10-09 13:42:44| Biotech - Topix.net
Cubist is testing a new antibacterial in children which has the potential to fight a serious type of diarrhea common to cancer patients called Clostridium difficile more effectively and cheaply than current drugs. The Lexington drug company plans to present results of an early-stage trial this weekend which it says will give early insight into the possibility of using a drug it acquired last year, called Dificid, in kids.
Tags: results
test
children
sees